3SBio, Inc. and Isotechnika Pharma, Inc. have signed a development and commercialization agreement for voclosporin, a next-gen calcineurin inhibitor being developed for the prevention of organ rejection and the treatment of autoimmune diseases. Isotechnika will grant 3SBio exclusive rights to all transplant and autoimmune indications of voclosporin in China, including Hong Kong and Taiwan, and will receive an upfront licensing payment of $1.5 million. 3SBio will be responsible for the clinica...